经盆腔动脉灌注化疗在晚期及复发性宫颈癌治疗中的应用价值  

Pelvic Intraarterial Chemotherapy for Patients with Advanced and Recurrent Cervical Carcinoma

作　　者：程祝忠[1] 杨宇洁[1] 李燎原[1] 席晓秋[1] 许国辉[1] 冯斌[1] 

机构地区：[1]四川省肿瘤医院影像科,四川成都610041

出　　处：《四川肿瘤防治》2004年第3期137-139,共3页Sichuan Journal of Cancer Control

摘　　要：目的 :探讨盆腔动脉灌注化疗在晚期及复发性宫颈癌治疗中的最佳时机及其价值。方法 :对 35例晚期、治疗后复发或未控的宫颈癌患者 ,行盆腔动脉灌注化疗。治疗疗效和毒性均按世界卫生组织 (WTO)制定标准判定。结果 :临床有效率为 19例 (5 4 0 % ) ,其平均生存期 95 0个月。介入治疗前经过其化治疗但病情未控或复发的 2 2例 ,有效缓解 1例 (4 5 % ) ,部分缓解 7例 (31 7% ) ,其平均生存期为 18 9个月 ,中位生存期仅为 14 0个月。结论 :对于晚期宫颈癌患者尽可能在手术及放射治疗同时进行盆腔动脉灌注化疗 ,以提高疗效 ,延长生存期。Objective:To evaluate the clinical efficacy of intraarterial chemotherapy (IAC)for patients with advanced and/or recurrent cervical cancer,and to determine the optimal time of chemotherapy administration.Methods:From February 1991 to December 1998,35 patients with pathologically comfirmed advanced and recurrent cervical cancar were treated with intraaterial chemothempy in our hospital.The age of the patients ranged 25 to 72 years,with a mean age of 45 years.IAC was administered for 1～3 courses every 4～6 weeks for each patient.The Seldinger'technique was used in all patients.Results:The mean follow-up was 24.5 months (range,4.0 to 150.0 month).Eight patients had a complete response,and eleven had a partial response ,no change in eight patients,and disease progressed in 4 patients.The overall response rate was 54%(CR,8,PR,11).Conclusion:IAC should be administered prior to surgery and/or radiotherapy,or concurrently with pelvic radiation to improve the response and survival rate for patients with advanced and recurrent cervical cancer.

关 键 词：经盆腔动脉灌注化疗 晚期宫颈癌 复发性宫颈癌 介入治疗 

分 类 号：R737.33[医药卫生—肿瘤]